Replies to post #97973 on Biotech Values

[turtlepower]

but I do like how AZN isn't the least bit afraid to partner with small-cap bio on interesting projects. I like the AZN deal with RIGL for R788 as potentially one of the first oral RA treatments to market. There's also the deal with TRGT for the depression drug that has shown good results to date, along with several related CNS programs.

So i assume you no longer consider syk inhibitors risky and russian trial sites irrelevant? :)